MODIFIED T-CELLS FOR USE IN THE TREATMENT OF HEAD AND NECK CANCER
The disclosure relates to a method of treating head and neck cancer, and to a population of modified immunoresponsive cells expressing a heterologous TCR for use in such method.
1 . A method of treating head and neck cancer in an individual, comprising administering to the individual a population of modified T cells comprising a heterologous CD8 co-receptor and a heterologous T-cell receptor (TCR) capable of binding to a peptide antigen of MAGE-A4.
2 . The method of claim 1 , wherein the method further comprises administering a checkpoint inhibitor to the individual, optionally wherein the population of modified T cells and the checkpoint inhibitor are administered in the same line of therapy.
3 . The method of claim 2 , wherein:
(a) administration of the checkpoint inhibitor begins before administration of the population of modified T cells, and continues after administration of the population of modified T cells; or
(b) administration of the checkpoint inhibitor begins at the same time as or after administration of the population of modified T cells, and continues after administration of the population of modified T cells.
4 . The method of claim 2 , the checkpoint inhibitor comprises a Programmed Death-1 (PD-1) axis binding antagonist, optionally pembrolizumab.
5 . The method of claim 1 , wherein the method further comprises administering an additional anti-cancer therapy to the individual, optionally wherein:
(a) population of modified T cells and the additional anti-cancer therapy are administered in the same line of therapy; and/or
(b) the additional anti-cancer therapy is a chemotherapy.
6 . The method of claim 5 , wherein:
(a) administration of the additional anti-cancer therapy begins before administration of the population of modified T cells, and continues after administration of the population of modified T cells; or
(b) administration of the additional anti-cancer therapy begins at the same time as or after administration of the population of modified T cells, and continues after administration of the population of modified T cells.
7 . The method of claim 1 , wherein the head and neck cancer is relapsed head and neck cancer.
8 . The method of claim 7 , wherein the head and neck cancer has relapsed following curative intent treatment for locally advanced head and neck cancer, optionally wherein:
(a) the curative intent treatment comprises surgical resection and/or radiation therapy; and/or
(b) the curative intent treatment comprises systemic therapy.
9 . The method of claim 7 , wherein:
(a) the method comprises administering a checkpoint inhibitor to the individual and administration of the checkpoint inhibitor begins at the same time as or after administration of the population of modified T cells and continues after administration of the population of modified T cells; and/or
(b) the method comprises administering an additional anti-cancer therapy to the individual and administration of the additional anti-cancer therapy begins at the same time as or after administration of the population of modified T cells and continues after administration of the population of modified T cells, optionally wherein the additional anti-cancer therapy is a chemotherapy.
10 . The method of claim 1 , wherein the individual has not previously been treated for the head and neck cancer, optionally wherein the head and neck cancer is newly metastatic or unresectable locally advanced head and neck cancer.
11 . The method of claim 10 , wherein:
(a) the method comprises administering a checkpoint inhibitor to the individual, and administration of the checkpoint inhibitor begins before or at the same time as administration of the population of modified T cells and continues after administration of the population of modified T cells; or
(b) the method comprises administering an additional anti-cancer therapy to the individual, and administration of the additional anti-cancer therapy begins before or at the same time as administration of the population of modified T cells and continues after administration of the population of modified T cells, optionally wherein the additional anti-cancer therapy is a chemotherapy.
12 . The method of claim 1 , wherein:
(a) the population of modified T cells is administered as soon as possible after diagnosis of the head and neck cancer; and/or
(b) the population of modified T cells is administered as a single dose.
13 . The method of claim 1 , wherein:
(a) the heterologous TCR binds to GVYDGREHTV (SEQ ID NO: 1) in complex with an HLA molecule;
(b) the heterologous TCR comprises an alpha chain amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2 and a beta chain amino acid sequence having at least 80% sequence identity to SEQ ID NO: 3; and/or
(c) the CD8 co-receptor is CD8α.
14 . The method of claim 1 , wherein the modified T cells are autologous with respect to the individual, optionally wherein the method comprises producing the population by:
(a) obtaining peripheral blood mononuclear cells (PBMCs) from the individual;
(b) selecting T cells from the PBMCs; and
(c) modifying the selected T cells to express the heterologous CD8 co-receptor and the heterologous TCR;
optionally wherein the head and neck cancer is relapsed head and neck cancer and wherein at least one of step (a) to (c) are performed prior to relapse.
15 . A population of modified T cells comprising a heterologous CD8 co-receptor and a heterologous T-cell receptor capable of binding to a peptide antigen of MAGE-A4, for use in the method of claim 1 .